Restoring balance.
Renewing life.

Akero is pioneering novel therapies to transform the lives of people living with serious metabolic diseases.
Learn More

Advancing Efruxifermin (EFX) for NASH

Our flagship EFX program is designed to be a differentiated, potentially best-in-class treatment for non-alcoholic steatohepatitis (NASH)

Ongoing Clinical Studies

We have multiple ongoing clinical trials to evaluate our investigational drug, EFX, as a treatment for NASH.

Recent Press Releases from Akero

We’re looking for talented individuals driven to make a difference for patients.

We’re looking for talented individuals driven to make a difference for patients.